U.S., Nov. 20 -- ClinicalTrials.gov registry received information related to the study (NCT07947823) titled 'ASTAR: Sacituzumab Govitecan For Breast Cancer' on Nov. 13.

Brief Summary: The goal of this clinical trial is to assess the safety and tolerability of sacituzumab govitecan followed by docetaxel and cyclophosphamide for individuals with high-risk early-stage HR+/HER2- breast cancer. The main questions it aims to answer are:

* Is sacituzumab govitecan safe for individuals with this type of cancer?

* Is sacituzumab govitecan effective in curing this type of cancer? Participants will receive up to 8 cycles of sacituzumab govitecan with chemotherapy.

Study Start Date: April 21, 2027

Study Type: INTERVENTIONAL

Condition: Breast Can...